PARP1 and cancer: Given the current challenges for PARP inhibitor cancer therapies, such as patient selection, treatment dosimetry and resistance to PARP therapy, the development of [18F]rucaparib and other radiolabelled PARP-targeting imaging agents may offer a way to overcome these challenges and improve treatment outcome for patients.